Blockchain Registration Transaction Record

Cybin Advances Mental Health Treatment with EMBRACE Phase 3 Study in Europe

Cybin Inc. receives European approval for EMBRACE Phase 3 study, testing CYB003 for Major Depressive Disorder, marking a leap in mental health treatment innovation.

This news is significant as it highlights Cybin's progress in developing innovative treatments for Major Depressive Disorder, a condition affecting millions worldwide. The approval to conduct the EMBRACE Phase 3 study in multiple European countries marks a pivotal step towards offering new hope for individuals with inadequately controlled MDD symptoms. The development of CYB003, with its Breakthrough Therapy Designation, underscores the potential for deuterated psilocin analogs to revolutionize mental health care, providing long-lasting relief where current treatments fall short.